Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: Pathological synergy of Alzheimer's disease and diabetes mellitus

Journal of Neuroscience Research

Volumn 90, Issue 10, 2012, Pages 1989-1996

  Valente, Tony ^a,b   Gella, Alejandro ^c   Solé, Montse ^a   Durany, Núria ^c   Unzeta, Mercedes ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Advanced glycation end products; Alzheimer's disease; Amyloid ; Cerebral blood vessels; Diabetes mellitus; Immunohistochemistry; SSAO VAP 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINE OXIDASE (COPPER CONTAINING); AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA ANTIGEN; VASCULAR ADHESION PROTEIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; ASTROCYTE; BLOOD VESSEL INJURY; BRAIN BLOOD VESSEL; CASE REPORT; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MICROPHOTOGRAPHY; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINE OXIDASE (COPPER-CONTAINING); AMYLOID BETA-PEPTIDES; BLOOD VESSELS; CEREBROVASCULAR CIRCULATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HIPPOCAMPUS; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROGLIA; OXIDATIVE STRESS; PLAQUE, AMYLOID; SUPEROXIDE DISMUTASE; TAU PROTEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84864843477     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23092     Document Type: Article

References (63)

1. Airas L, Lindsberg PJ, Karjalainen-Lindsberg ML, Mononen I, Kotisaari L, Smith DJ, Jalkanen S. 2008. Vascular adhesion protein-1 in human ischaemic stroke. Neuropathol Appl Neurobiol 34: 394-402.
2. Anger T, Pohle FK, Kandler L, Barthel T, Ensminger SM, Fischlein T, Weyand M, Stumpf C, Daniel WG, Garlichs CD. 2007. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Exp Mol Pathol 83: 435-442.
3. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. 2004. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666.
4. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. 2002. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105: 816-822.
5. Bell RD, Zlokovic BV. 2009. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-113.
6. Bono P, Salmi M, Smith DJ, Leppanen I, Horelli-Kuitunen N, Palotie A, Jalkanen S. 1998. Isolation, structural characterization, and chromosomal mapping of the mouse vascular adhesion protein-1 gene and promoter. J Immunol 161: 2953-2960.
7. Boomsma F, Derkx FH, van den Meiracker AH, Man in't Veld AJ, Schalekamp MA. 1995. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci 88: 675-679.
8. Boomsma F, van Veldhuisen DJ, de Kam PJ, Man in't Veld AJ, Mosterd A, Lie KI, Schalekamp MA. 1997. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 33: 387-391.
9. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
10. Castillo V, Lizcano JM, Visa J, Unzeta M. 1998. Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. Neurochem Int 33: 415-423.
11. Chen K, Maley J, Yu PH. 2006. Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 99: 1413-1424.
12. Deane R, Zlokovic BV. 2007. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197.
13. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913.
14. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43: 333-344.
15. del Mar Hernandez M, Esteban M, Szabo P, Boada M, Unzeta M. 2005. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett 384: 183-187.
16. Dukic-Stefanovic S, Schinzel R, Riederer P, Münch G. 2001. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2: 19-34.
17. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Yan S, Schmidt AM, Chen JX, Yan SS. 2010. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 24: 1043-1055.
18. Ferrer I, Lizcano JM, Hernández M, Unzeta M. 2002. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 321: 21-24.
19. Garpenstrand H, Ekblom J, Bäcklund LB, Oreland L, Rosenqvist U. 1999. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet Med 16: 514-521.
20. Gella A, Durany N. 2009. Oxidative stress in Alzheimer disease. Cell Adhes Migrat 3: 88-93.
21. Gokturk C, Garpenstrand H, Nilsson J, Nordquist J, Oreland L, Forsberg-Nilsson K. 2003. Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice. Biochim Biophys Acta 1647: 88-91.
22. Gokturk C, Nordquist J, Sugimoto H, Forsberg-Nilsson K, Nilsson J, Oreland L. 2004. Semicarbazide-sensitive amine oxidase in transgenic mice with diabetes. Biochem Biophys Res Commun 325: 1013-1020.
23. Gubisne-Haberle D, Hill W, Kazachkov M, Richardson JS, Yu PH. 2004. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 310: 1125-1132.
24. Hernandez M, Solé M, Boada M, Unzeta M. 2006. Soluble semicarbazide sensitive amine oxidase (SSAO) catalysis induces apoptosis in vascular smooth muscle cells. Biochim Biophys Acta 1763: 164-173.
25. Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J. 2010. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 41: 1528-1535.
26. Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J. 2012. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovasc Dis 33: 55-63.
27. Hsu MJ, Hsu CY, Chen BC, Chen MC, Ou G, Lin CH. 2007. Apoptosis signal-regulating kinase 1 in amyloid β peptide-induced cerebral endothelial cell apoptosis. J Neurosci 27: 5719-5729.
28. Jeynes B, Provias J. 2011. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res 89: 22-28.
29. Karadi I, Meszaros Z, Csanyi A, Szombathy T, Hosszufalusi N, Romics L, Magyar K. 2002. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker or carotid agherosclerosis. Clin Chim Acta 323: 139-146.
30. Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Münch G. 2004. Differential effects of "advanced glycation endproducts" and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 111: 427-439.
31. Lizcano JM, Tipton KF, Unzeta M. 1998. Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J 331: 69-78.
32. Luchsinger JA, Tang MX, Shea S, Mayeux R. 2004. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63: 1187-1192.
33. Lyles GA. 1996. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 28: 259-274.
34. Maeda M, Takagi H, Hattori H, Matsuzaki T. 1997. Localization of manganese superoxide dismutase in the cerebral cortex and hippocampus of Alzheimer-type senile dementia. Osaka City Med J 43: 1-5.
35. Mathys KC, Ponnampalam SN, Padival S, Nagaraj RH. 2002. Semicarbazide-sensitive amine oxidase in aortic smooth muscle cells mediates synthesis of a methylglyoxal-AGE: implications for vascular complications in diabetes. Biochem Biophys Res Commun 297: 863-869.
36. Mészáros Z, Szombathy T, Raimondi L, Karádi I, Romics L, Magyar K. 1999. Elevated sèrum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48: 113-117.
37. Münch G, Deuther-Conrad W, Gasic-Milenkovic J. 2002. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease-a target for neuroprotective treatment strategies? J Neural Transm Suppl 303-307.
38. Nunes SF, Figuereido IV, Pereira JS, Soares PJ, Caramona MM, Callingham B. 2010. Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes. Acta Diabetol 47: 179-182.
39. Plaschke K, Kopitz J, Siegelin M, Schliebs R, Salkovic-Petrisic M, Riederer P, Hoyer S. 2010. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19: 691-704.
40. Precious E, Lyles GA. 1988. Properties of a semicarbazide-sensitive amine oxidase in human umbilical artery. J Pharm Pharmacol 40: 627-633.
41. Salmi M, Jalkanen S. 1992. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257: 1407-1409.
42. Schmidt AM, Yan SD, Wautier JL, Stern D. 1999. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497.
43. Selkoe DJ. 2001. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3: 75-80.
44. Solé M, Hernandez-Guillamon M, Boada M, Unzeta M. 2008. p53 Phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1. Biochim Biophys Acta 1783: 1085-1094.
45. Somfai GM, Knippel B, Ruzicska E, Stadler K, Tóth M, Salacz G, Magyar K, Somogyi A. 2006. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats. Neurochem Int 48: 746-752.
46. Soontornniyomkij V, Choi C, Pomakian J, Vinters V. 2010. High-definition characterization of cerebral β-amyloid angiopathy in Alzheimer's disease. Hum Pathol 41: 1601-1608.
47. Stern D, Yan SD, Yan SF, Schmidt AM. 2002. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54: 1615-1625.
48. Stolen CM, Madanat R, Marti L, Kari S, Yegutkin GG, Sariola H, Zorzano A, Jalkanen S. 2004. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 18: 702-704.
49. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R. 2010. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107: 7036-7041 [E-pub 15 March 2010].
50. Takeuchi M, Yamagishi S. 2008. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm 14: 973-978.
51. Thornalley PJ. 2002. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50: 37-57.
52. Unzeta M, Solé M, Boada M, Hernández M. 2007. Semicarbazide-sensitiveamine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease. J Neural Transm 114: 857-862.
53. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. 2010. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 37: 67-76.
54. Vinters HV, Miller BL, Pardridge WM. 1988. Brain amyloid and Alzheimer disease. Ann Intern Med 109: 41-54.
55. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 91: 4766-4770.
56. Wang T, Fu F, Han B, Zhang L, Zhang X. 2012. Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end product-mediated neuroinflammation. J Neuroimmunol [E-pub ahead of print 12 March 2012].
57. Wang X, Zheng W, Xie JW, Wang T, Wang SL, Teng WP, Wang ZY. 2010. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegen 5: 46.
58. Wilhelmus M, Otte-Höller I, Van Triel J, Veerhuis R, Maat-Schieman M, Bu G, de Waal R, Verbeek M. 2007. Lipoprotein receptor-related protein-1 mediates amyloid-β-mediated cell death of cerebrovascular cells. Am J Pathol 171: 1989-1999.
59. Yan SD, Bierhaus A, Nawroth PP, Stern DM. 2009. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 16: 833-843.
60. Yan SF, Ramasamy R, Schmidt AM. 2008. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4: 285-293.
61. Yu PH. 2001. Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Med Hypoth 57: 175-179.
62. Yu PH, Zuo DM. 1997. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advaned glycation and diabetic complications. Diabetologia 40: 1243-1250.
63. Yu PH, Zuo DM, Davis BA. 1994. Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO): species heterogeneity and stereoisomeric specificity. Biochem Pharmacol 47: 1055-1059.